DBVT News and Press, DBV Technologies S.A. From 12/17/25

A look at the top 10 most actives in the United States Direxion Daily Semiconductor Bear 3X Shares (SOXS) rose 11.5% to $3.7814 on volume of 536,540,294 shares Agape ATP Corporation (ATPC) rose 65.3% to $0.148788 on volume of 337,143,999 shares VYNE Therapeutics Inc. (VYNE) rose 58.0% to $0...

2025-12-17 06:56:09 ET More on DBV Technologies DBV Technologies S.A. (DBVT) Discusses Positive Phase III VITESSE Trial Results for Peanut Allergy Patch in Young Children Transcript DBV Technologies: Uncertainty Still Exists Despite Recent 90% Rally DBV Technologies ...

2025-12-16 22:10:05 ET DBV Technologies S.A. (DBVT) Discusses Positive Phase III VITESSE Trial Results for Peanut Allergy Patch in Young Children December 16, 2025 5:00 PM EST... Read the full article on Seeking Alpha For further details see: DBV Technologies S.A. (DBVT) Dis...

Châtillon, France, December 16, 2025 DBV Technologies Announces Positive Topline Results from Phase 3 VITESSE Trial of VIASKIN® Peanut Patch in Peanut Allergic Children Aged 4-7 Years VITESSE met its primary endpoint: the lower bound of the 95% confidence interval (CI) o...

2025-12-11 01:46:33 ET Today, I am putting DBV Technologies S.A. ( DBVT ) in the spotlight. The company is based overseas and therefore gets relatively little coverage from Wall Street. The company is moving towards filing a key marketing application early next year and could be in ...

Information Regarding the Total Number of Voting Rights and Total Number of Shares of the Company as of November 30, 2025 (Article 223-16 of the General Regulations of the Autorité des Marchés Financiers ) Market : NYSE Euronext Paris ISIN Code: FR 0010417345 ...

Châtillon, France, November 11, 2025 DBV Technologies Announces Last Patient Visit Completed in VITESSE Phase 3 Clinical Trial of VIASKIN ® Peanut Patch in Peanut Allergic Children Aged 4-7 Years Company remains on track for VITESSE topline data in Q4 of this...

Châtillon, France, November 4, 2025 DBV Technologies to Participate in the Guggenheim 2 nd Annual Healthcare Innovation Conference DBV Technologies (Euronext: DBV – ISIN: FR0010417345 – Nasdaq Stock Market: DBVT – CUSIP: 23306J309), a cli...

Chatillion, France, November 3, 2025 DBV Technologies Appoints Industry Leader Kevin Trapp as Chief Commercial Officer DBV Technologies (Euronext: DBV – ISIN: FR0010417345 – Nasdaq Stock Market: DBVT), a clinical-stage biopharmaceutical company, today announced the app...

Information Regarding the Total Number of Voting Rights and Total Number of Shares of the Company as of October 31, 2025 (Article 223-16 of the General Regulations of the Autorité des Marchés Financiers ) Market : NYSE Euronext Paris ISIN Code: FR 0010417345 ...